Zometa 4 mg ( Zoledronic ) vial for IV infusion

Zometa 4 mg ( Zoledronic ) vial for IV infusion

Description:

Zometa 4 mg/5 ml concentrated solution for i.v. infusion is a prescription oncology and bone-health medicine containing zoledronic acid, a third-generation bisphosphonate that inhibits osteoclastic bone resorption. It is used in adults to manage bone complications associated with cancer and to treat hypercalcemia of malignancy. Zometa is supplied as a sterile concentrate in a vial that must be diluted and administered only as an intravenous infusion by healthcare professionals in a hospital or clinical setting.

Indications:

• Treatment of hypercalcemia of malignancy (tumor-induced hypercalcemia).
• Prevention of skeletal-related events (such as pathological fractures, spinal cord compression, or need for radiation or surgery to bone) in patients with advanced malignancies involving bone (e.g., multiple myeloma, solid tumors with bone metastases).
• Reduction of bone pain associated with bone metastases (as part of comprehensive cancer care).
• Adjunctive management of cancer-related bone disease where inhibition of bone resorption is required, as directed by an oncologist.

Active Ingredients / Key Components:

• Zoledronic acid (as zoledronic acid monohydrate) – 4 mg per 5 ml concentrated solution for i.v. infusion.
• Excipients (such as mannitol, sodium citrate, water for injections) – exact composition and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package insert for full excipient list.

Dosage & Administration / How to Use:

• Zometa must be administered only by healthcare professionals experienced in intravenous bisphosphonate use.
• Adults: The usual dose for prevention of skeletal-related events in patients with bone metastases is 4 mg zoledronic acid given as a single i.v. infusion over at least 15 minutes, typically every 3 to 4 weeks, as prescribed by the treating oncologist.
• For treatment of hypercalcemia of malignancy, a single 4 mg i.v. infusion is commonly used; dosing frequency and potential repeat dosing depend on clinical response and renal function, strictly according to physician guidance.
• Preparation: The 4 mg/5 ml concentrate must be further diluted in 100 ml of calcium-free infusion solution (such as 0.9% sodium chloride or 5% glucose) before administration. Do not administer as an undiluted bolus injection.
• Infusion time: Administer the diluted solution as a constant-rate intravenous infusion over no less than 15 minutes.
• Renal impairment: Dose adjustment and extended dosing interval may be required in patients with reduced kidney function; creatinine clearance should be assessed before each dose. Follow official prescribing information and physician instructions.
• Hydration: Patients should be adequately hydrated before and after Zometa infusion, especially when being treated for hypercalcemia, unless contraindicated.
• Do not self-administer. This medicine is not for intramuscular, subcutaneous, or oral use; it is strictly for intravenous infusion.

Clinical Benefits:

• Helps control tumor-induced hypercalcemia by reducing excessive bone resorption and lowering elevated serum calcium levels.
• Reduces the risk of skeletal-related events (fractures, spinal cord compression, need for radiation or surgery to bone) in patients with advanced cancers involving bone.
• Provides sustained inhibition of osteoclast activity, contributing to improved bone strength and stability in cancer-related bone disease.
• May help alleviate bone pain and improve quality of life when used as part of a comprehensive oncology treatment plan.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to zoledronic acid, other bisphosphonates, or any component of the formulation.
• Use is contraindicated in patients with severe renal impairment (specific creatinine clearance thresholds as per official prescribing information) unless the potential benefit outweighs the risk and under strict specialist supervision.
• Risk of osteonecrosis of the jaw (ONJ): Use with caution in patients with dental disease, invasive dental procedures, poor oral hygiene, or concomitant corticosteroid or antiangiogenic therapy. Dental examination and preventive dental care are recommended before starting treatment.
• Monitor renal function (serum creatinine, creatinine clearance) before each dose; adjust dose or withhold treatment in case of renal deterioration.
• Monitor serum calcium, phosphate, and magnesium levels; supplementation with calcium and vitamin d may be required in some patients to prevent hypocalcemia, as advised by the physician.
• Use with caution in patients with pre-existing hypocalcemia, mineral metabolism disturbances, or severe hepatic impairment.
• May cause severe bone, joint, or muscle pain; inform your doctor if such symptoms occur.
• Pregnancy and lactation: Zometa is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose, as advised by their doctor.
• Not recommended for use in children and adolescents due to limited safety and efficacy data.
• Consult your doctor before use if pregnant, nursing, taking medications, or have medical conditions such as kidney disease, heart failure, electrolyte imbalance, dental problems, or if you are on diuretics, aminoglycosides, or other nephrotoxic drugs.
• Not intended to diagnose, treat, cure, or prevent any disease without a physician’s prescription and supervision.
• Keep out of reach of children.
• Use only as directed by an oncologist or specialist; misuse or incorrect administration may cause serious adverse effects.

Side Effects:

• Common side effects may include flu-like symptoms (fever, chills, fatigue, muscle or joint pain), headache, nausea, vomiting, loss of appetite, constipation or diarrhea, and injection-site reactions.
• Laboratory abnormalities such as hypocalcemia, hypophosphatemia, hypomagnesemia, or elevated serum creatinine may occur; regular blood tests are required.
• Less common but serious side effects include osteonecrosis of the jaw (jaw pain, swelling, loose teeth, non-healing sores in the mouth), severe bone, joint, or muscle pain, eye inflammation (uveitis, scleritis), and atypical femoral fractures.
• Allergic reactions, including rash, itching, facial swelling, difficulty breathing, or severe dizziness, require immediate medical attention.
• Seek urgent medical care if you experience severe chest pain, shortness of breath, irregular heartbeat, seizures, severe kidney problems (reduced urine output, swelling of legs or ankles), or signs of severe electrolyte disturbance.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not freeze. Store at temperatures as recommended in the official package insert (typically below 30°c). After dilution, use the infusion solution within the time frame specified by the manufacturer or according to hospital protocols. Do not use if the solution is discolored or contains particulate matter.

Specifications:

• Form: Concentrated solution for intravenous infusion.
• Strength: 4 mg zoledronic acid per 5 ml vial.
• Route of administration: Intravenous infusion only.
• Packaging: Single-use glass vial containing 5 ml concentrate (exact pack configuration may vary by market; check local packaging).
• Intended users: Adult patients under the supervision of an oncologist or specialist physician.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.